Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/lurasidone-in-the-treatment-of-schizophrenia-results-of-a-double-blind-33aknCVupA
References (31)
-
T. Inada, C. Beasley, Y. Tanaka, D. Walker (2003)
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidolInternational Clinical Psychopharmacology, 18
-
Claire Wu, Jessica Yuen, H. Boyda, R. Procyshyn, Cathy Wang, Y. Asiri, C. Pang, W. Honer, A. Barr (2014)
An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with OlanzapinePLoS ONE, 9
-
(1976)
ECDEU assessment manual for psychopharmacology (revised) (pp. 76–338) -
G. Mankin (2015)
Lurasidone for the treatment of schizophrenia -
C. Correll, T. Lencz, A. Malhotra (2011)
Antipsychotic drugs and obesity.Trends in molecular medicine, 17 2
-
J. W. Newcomer (2005)
Second‐generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review, 19
-
A. Loebel, J. Cucchiaro, K. Sarma, Lei Xu, Chuanchieh Hsu, A. Kalali, A. Pikalov, S. Potkin (2013)
Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trialSchizophrenia Research, 145
-
(1976)
ECDEU Assessment Manual -
(2011)
The Columbia–Suicide Severity Rating -
H. Nasrallah, Robert Silva, D. Phillips, J. Cucchiaro, J. Hsu, Jane Xu, A. Loebel (2013)
Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.Journal of psychiatric research, 47 5
-
T. Ishibashi, T. Horisawa, K. Tokuda, T. Ishiyama, M. Ogasa, R. Tagashira, Kenji Matsumoto, Hiroyuki Nishikawa, Y. Ueda, Satoko Toma, Hitomi Oki, N. Tanno, I. Saji, Akira Ito, Y. Ohno, Mitsutaka Nakamura (2010)
Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor ActivityJournal of Pharmacology and Experimental Therapeutics, 334
-
W. Kroeze, S. Hufeisen, Beth Popadak, Sean Renock, SeAnna Steinberg, P. Ernsberger, K. Jayathilake, H. Meltzer, B. Roth (2003)
H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic DrugsNeuropsychopharmacology, 28
-
L. Citrome (2011)
Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second‐generation antipsychoticInternational Journal of Clinical Practice, 65
-
V. Simon, R. Winkel, M. Hert (2009)
Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.The Journal of clinical psychiatry, 70 7
-
(2013)
Efficacy and safety of lurasidone 80 mg / day and 160 mg / day in the treatment of schizophrenia : A randomized , double ‐ blind , placebo ‐ and active ‐ controlled trial -
J. Newcomer (2005)
Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs, 19
-
(2009)
Are weight gain and met -
Mitsutaka Nakamura, M. Ogasa, J. Guarino, D. Phillips, Joseph Severs, J. Cucchiaro, A. Loebel (2009)
Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.The Journal of clinical psychiatry, 70 6
-
K. Posner, Gregory Brown, B. Stanley, David Brent, K. Yershova, M. Oquendo, Glenn Currier, Glenn Melvin, L. Greenhill, S. Shen, J. Mann (2011)
The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.The American journal of psychiatry, 168 12
-
S. Kay, A. Fiszbein, L. Opler (1987)
The positive and negative syndrome scale (PANSS) for schizophrenia.Schizophrenia bulletin, 13 2
-
T. Laursen, M. Nordentoft, P. Mortensen (2014)
Excess early mortality in schizophrenia.Annual review of clinical psychology, 10
-
(1976)
ECDEU assessment manual for psychopharmacology (revised) -
(2005)
Second‐generation (atypical) antipsychotics -
M. Ogasa, Tatsuya Kimura, Mitsutaka Nakamura, J. Guarino (2012)
Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled studyPsychopharmacology, 225
-
M. Hert, J. Detraux, R. Winkel, Weiping Yu, C. Correll (2012)
Metabolic and cardiovascular adverse effects associated with antipsychotic drugsNature Reviews Endocrinology, 8
-
H. Meltzer, J. Cucchiaro, Robert Silva, M. Ogasa, D. Phillips, Jane Xu, A. Kalali, E. Schweizer, A. Pikalov, A. Loebel (2011)
Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.The American journal of psychiatry, 168 9
-
D. Bruijnzeel, Uma Suryadevara, R. Tandon (2014)
Antipsychotic treatment of schizophrenia: an update.Asian journal of psychiatry, 11
-
L. Citrome (2011)
Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.Clinical schizophrenia & related psychoses, 4 4
-
M. Sanford (2012)
LurasidoneCNS Drugs, 27
-
(2003)
H 1 ‐ histamine receptor affinity predicts short ‐ term weight gain for typical and atypical antipsychotic drugs -
A. Mitchell, D. Vancampfort, Amber Herdt, Weiping Yu, M. Hert (2013)
Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients.Schizophrenia bulletin, 39 2
- Publisher
- Wiley
- Copyright
- "© 2019 John Wiley & Sons Australia, Ltd"
- ISSN
- 1758-5864
- eISSN
- 1758-5872
- DOI
- 10.1111/appy.12352
- Publisher site
- See Article on Publisher Site
Abstract
Journal
Asia-Pacific Psychiatry – Wiley
Published: Jun 1, 2019
Keywords: ; ; ;